TWI683807B - 作為轉染重排（ｒｅｔ）抑制劑之新穎化合物 - Google Patents

作為轉染重排（ｒｅｔ）抑制劑之新穎化合物 Download PDF

Info

Publication number
TWI683807B
TWI683807B TW104129876A TW104129876A TWI683807B TW I683807 B TWI683807 B TW I683807B TW 104129876 A TW104129876 A TW 104129876A TW 104129876 A TW104129876 A TW 104129876A TW I683807 B TWI683807 B TW I683807B
Authority
TW
Taiwan
Prior art keywords
compound
formula
weight
cancer
ethoxy
Prior art date
Application number
TW104129876A
Other languages
English (en)
Chinese (zh)
Other versions
TW201625534A (en
Inventor
麥可 迪麥提諾
關慧萍
Original Assignee
英商葛蘭素史克智慧財產發展有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商葛蘭素史克智慧財產發展有限公司 filed Critical 英商葛蘭素史克智慧財產發展有限公司
Publication of TW201625534A publication Critical patent/TW201625534A/zh
Application granted granted Critical
Publication of TWI683807B publication Critical patent/TWI683807B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
TW104129876A 2014-09-10 2015-09-10 作為轉染重排（ｒｅｔ）抑制劑之新穎化合物 TWI683807B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2014086197 2014-09-10
WOPCT/CN2014/086197 2014-09-10
CN2015086995 2015-08-14
WOPCT/CN2015/086995 2015-08-14

Publications (2)

Publication Number Publication Date
TW201625534A TW201625534A (en) 2016-07-16
TWI683807B true TWI683807B (zh) 2020-02-01

Family

ID=54186249

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104129876A TWI683807B (zh) 2014-09-10 2015-09-10 作為轉染重排（ｒｅｔ）抑制劑之新穎化合物

Country Status (36)

Country Link
US (4) US9918974B2 (enExample)
EP (2) EP3517526B1 (enExample)
JP (2) JP6538154B2 (enExample)
KR (1) KR20170045350A (enExample)
CN (1) CN107074768B (enExample)
AU (1) AU2015313841B2 (enExample)
BR (1) BR112017004900A2 (enExample)
CA (1) CA2960768A1 (enExample)
CL (1) CL2017000588A1 (enExample)
CO (1) CO2017002273A2 (enExample)
CR (1) CR20170093A (enExample)
CY (1) CY1121661T1 (enExample)
DK (1) DK3191450T3 (enExample)
DO (1) DOP2017000059A (enExample)
EA (1) EA033544B1 (enExample)
ES (2) ES2816453T3 (enExample)
HR (1) HRP20190815T1 (enExample)
HU (1) HUE044604T2 (enExample)
IL (1) IL250908B (enExample)
LT (1) LT3191450T (enExample)
MA (1) MA40581A (enExample)
ME (1) ME03432B (enExample)
MX (1) MX373863B (enExample)
MY (1) MY181913A (enExample)
PE (1) PE20170705A1 (enExample)
PH (1) PH12017500425B1 (enExample)
PL (1) PL3191450T3 (enExample)
PT (1) PT3191450T (enExample)
RS (1) RS58813B1 (enExample)
SG (1) SG11201701694QA (enExample)
SI (1) SI3191450T1 (enExample)
SM (1) SMT201900304T1 (enExample)
TW (1) TWI683807B (enExample)
UA (1) UA122213C2 (enExample)
UY (1) UY36293A (enExample)
WO (1) WO2016038552A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
BR112017004897A2 (pt) 2014-09-10 2017-12-12 Glaxosmithkline Ip Dev Ltd compostos inovadores como inibidores rearranjados durante a transfecção (ret)
EP3517526B1 (en) 2014-09-10 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Pyridinones as rearranged during transfection (ret) inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US20210290620A1 (en) 2017-05-15 2021-09-23 Blueprint Medicines Corporation Combinations of RET Inhibitors and mTORC1 Inhibitors and Uses Thereof for the Treatment of Cancer Mediated by Aberrant RET Activity
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
SG11202009681YA (en) 2018-04-03 2020-10-29 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
WO2021243192A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CR20220666A (es) 2020-05-29 2023-05-05 Blueprint Medicines Corp Composiciones farmacéuticas de pralsetinib
TWI786742B (zh) * 2020-07-23 2022-12-11 大陸商深圳晶泰科技有限公司 吡啶酮類化合物及其製備方法和應用
CN119768181A (zh) 2022-08-24 2025-04-04 东丽株式会社 用于癌的治疗和/或预防的药品

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046802A1 (en) * 2006-10-16 2008-04-24 Novartis Ag Phenylacetamides useful as protein kinase inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120046290A1 (en) 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
CA2315720A1 (en) 1997-12-22 1999-07-01 Bayer Corporation Inhibition of p38 kinase activity using substituted heterocyclic ureas
JP4437270B2 (ja) * 1997-12-22 2010-03-24 バイエル コーポレイション 置換複素環式尿素を用いたｒａｆキナーゼの阻害
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
MXPA02001498A (es) 1999-08-12 2003-07-21 Pharmacia & Italia S P A Derivados de 3(5)-amino-pirazol, procedimiento para la preparacion de los mismos y usos como agentes antitumorales.
AU2002215053A1 (en) * 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
DE10201764A1 (de) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituierte 4-Aminopyridin-Derivate
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
JPWO2004024694A1 (ja) 2002-09-10 2006-01-05 杏林製薬株式会社 ４−置換アリール−５−ヒドロキシイソキノリノン誘導体
CN1838958A (zh) 2003-08-22 2006-09-27 贝林格尔·英格海姆药物公司 治疗慢性阻塞性肺病和肺动脉高血压的方法
TW200530236A (en) * 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
PL1836169T3 (pl) * 2004-12-28 2012-07-31 Kinex Pharmaceuticals Llc Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
GB0507575D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US8247556B2 (en) * 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
ES2500165T3 (es) 2006-06-29 2014-09-30 Kinex Pharmaceuticals, Llc Composiciones de biarilo y métodos para modular una cascada de quinasas
WO2008033562A2 (en) * 2006-09-15 2008-03-20 Xcovery, Inc. Kinase inhibitor compounds
PL2848610T3 (pl) * 2006-11-15 2018-01-31 Ym Biosciences Australia Pty Inhibitory aktywności kinazy
KR20120059558A (ko) 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 바이아릴 화합물 및 이의 사용 방법
EP2651930B1 (en) 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
MX2015012286A (es) * 2013-03-15 2016-05-31 Glaxosmithkline Ip Dev Ltd Derivados de piridina como inhibidores de cinasa reordenada durante transfección.
AR095308A1 (es) 2013-03-15 2015-10-07 Glaxosmithkline Ip Dev Ltd Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento
EP3517526B1 (en) 2014-09-10 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Pyridinones as rearranged during transfection (ret) inhibitors
BR112017004897A2 (pt) 2014-09-10 2017-12-12 Glaxosmithkline Ip Dev Ltd compostos inovadores como inibidores rearranjados durante a transfecção (ret)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046802A1 (en) * 2006-10-16 2008-04-24 Novartis Ag Phenylacetamides useful as protein kinase inhibitors

Also Published As

Publication number Publication date
US20190247382A1 (en) 2019-08-15
MY181913A (en) 2021-01-14
CY1121661T1 (el) 2020-07-31
US9918974B2 (en) 2018-03-20
PH12017500425A1 (en) 2017-07-31
HUE044604T2 (hu) 2019-11-28
ES2816453T3 (es) 2021-04-05
UY36293A (es) 2016-04-01
TW201625534A (en) 2016-07-16
EP3517526B1 (en) 2020-08-19
LT3191450T (lt) 2019-06-10
JP6538154B2 (ja) 2019-07-03
JP6728447B2 (ja) 2020-07-22
SMT201900304T1 (it) 2019-07-11
CA2960768A1 (en) 2016-03-17
HRP20190815T1 (hr) 2019-07-12
US10292975B2 (en) 2019-05-21
US20190022078A1 (en) 2019-01-24
JP2017527578A (ja) 2017-09-21
MX2017003114A (es) 2017-11-15
US10111866B2 (en) 2018-10-30
ME03432B (me) 2020-01-20
AU2015313841A1 (en) 2017-03-23
EP3191450B1 (en) 2019-04-10
EA033544B1 (ru) 2019-10-31
BR112017004900A2 (pt) 2017-12-12
EA201790546A1 (ru) 2017-07-31
IL250908B (en) 2020-11-30
SI3191450T1 (sl) 2019-07-31
CL2017000588A1 (es) 2017-10-06
CN107074768A (zh) 2017-08-18
RS58813B1 (sr) 2019-07-31
SG11201701694QA (en) 2017-04-27
PL3191450T3 (pl) 2019-08-30
JP2019163316A (ja) 2019-09-26
PT3191450T (pt) 2019-05-29
EP3517526A1 (en) 2019-07-31
CN107074768B (zh) 2019-12-10
US20170340617A1 (en) 2017-11-30
EP3191450A1 (en) 2017-07-19
MA40581A (fr) 2019-04-10
US10709695B2 (en) 2020-07-14
ES2725704T3 (es) 2019-09-26
PH12017500425B1 (en) 2017-07-31
WO2016038552A1 (en) 2016-03-17
UA122213C2 (uk) 2020-10-12
CR20170093A (es) 2017-07-17
IL250908A0 (en) 2017-04-30
KR20170045350A (ko) 2017-04-26
MX373863B (es) 2020-03-26
DK3191450T3 (da) 2019-05-20
DOP2017000059A (es) 2017-03-31
PE20170705A1 (es) 2017-05-21
CO2017002273A2 (es) 2017-06-20
AU2015313841B2 (en) 2018-03-08
US20180147194A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
JP6728447B2 (ja) Ｒｅｔ（ｒｅａｒｒａｎｇｅｄ ｄｕｒｉｎｇ ｔｒａｎｓｆｅｃｔｉｏｎ）キナーゼ阻害剤としてのピリジン誘導体
CN109745316B (zh) 用于治疗癌症的联合治疗
JP5864545B2 (ja) インドール
WO2017145050A1 (en) Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
EP2970191B1 (en) Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors
TWI623533B (zh) 作為檢測點激酶1 (chk1)抑制劑之3,5-二取代吡唑及其製備及應用
CN116368130A (zh) 杂环化合物及其用途
CN118574836A (zh) 用于治疗癌症的环状2-胺基-3-氰基噻吩及衍生物
EA021927B1 (ru) 2-[(5-хлор-2-{[3-метил-1-(1-метилэтил)-1н-пиразол-5-ил]амино}-4-пиридинил)амино]-n-(метилокси)бензамид в качестве ингибиторов fak и содержащая его фармацевтическая композиция
ES2745016T3 (es) Bromhidrato de N-((4,6-dimetil-2-oxo-L,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[L,1'-bifenil]-3-carboxamida para su uso en el tratamiento de un trastorno proliferativo celular del sistema hematológico
TW201041872A (en) Amino ester derivatives, salts thereof and methods of use
JP6122877B2 (ja) ユビキチン活性化酵素のピラゾロピリミジニル阻害剤
JP6816041B2 (ja) Ｚｅｓｔｅホモログ２エンハンサー阻害剤
CN116917273A (zh) 作为dnmt1抑制剂的经取代的吡啶
HK1237341B (en) Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
HK1237341A1 (en) Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
TW201127837A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees